Brainstorm Cell Therapeutics Inc. Aktie News

Executive Chairman und ehemalige FDA-Associate-Commissioner Peter J. Pitts wird Keynote-Vorträge zur Einrichtung eines FDA Abraham Accords Office und zur Umstrukturierung der NIH-Fördermodell für Forschungsgelder halten.

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), ein führender Entwickler von adulten Stammzelltherapeutika für neurodegenerative Erkrankungen, gab heute die Finanzergebnisse für das zweite Quartal zum 30. Juni 2026 bekannt und lieferte ein Unternehmens-Update. „Wir treiben weiterhin die Vorbereitungen voran und schließen die notwendigen Maßnahmen ab, um ...

Professor Jacob Frenkel wechselt in die Rolle des Senior Advisor. Peter J. Pitts wird NurOwn® in die Phase-3b-Studie führen; der Fortschritt erfolgt unter der ersten jemals für einen ALS-Therapeutikakandidaten gewährten Special Protocol Assessment. NEW YORK, 28. Juli 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), ein führender Entwickler innovativer autologer Zelltherapie...

Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenera...

Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors...

$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ --  May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction ...

NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update.     "The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDUR...

Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for...